Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 2014 Apr;19(4):426-8

Date

03/29/2014

Pubmed ID

24668327

Pubmed Central ID

PMC3983812

DOI

10.1634/theoncologist.2013-0231

Scopus ID

2-s2.0-84898429501 (requires institutional sign-in at Scopus site)   11 Citations

Abstract

Mucositis may limit the therapeutic window for mammalian target of rapamycin inhibitor-based combination therapy, necessitating treatment interruptions and/or dose reductions. Optimizing treatment or prophylactic interventions for mucositis will enable patients to continue effective treatment while maintaining good quality of life.

Author List

Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Male
Metformin
Middle Aged
Mucositis
Niacinamide
Protein Kinase Inhibitors
Retrospective Studies
Sirolimus
TOR Serine-Threonine Kinases
Treatment Outcome
Young Adult